A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
Status:
Completed
Trial end date:
2019-07-21
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared
with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients
with unresectable locally advanced or metastatic melanoma, as measured by progression-free
survival (PFS), assessed by the study site investigator.